A Phase 1b/2, Open-Label, Multi-center Study to Assess the Safety, Tolerability, Pharmacokinetics and Efficacy of SNB-101, in Extensive Stage Small Cell Lung Cancer
Latest Information Update: 03 Jun 2026
At a glance
- Drugs SNB 101 (Primary)
- Indications Small cell lung cancer
- Focus Adverse reactions; Pharmacokinetics; Therapeutic Use
- Acronyms SNB-101-101
- Sponsors SN BioScience
Most Recent Events
- 14 May 2026 Planned number of patients changed from 55 to 135, according to SN BioScience media release.
- 14 May 2026 According to the SN BioScience media release, company has initiated the first patient dosing in its global Phase 1b/2 clinical trial evaluating SNB 101 in patients with Extensive-Stage Small Cell Lung Cancer
- 01 Mar 2026 Status changed from not yet recruiting to recruiting.